Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WARNER-LAMBERT NEURONTIN USE IN NON-EPILEPTIC CONDITIONS UNDER STUDY; ANTIDIABETIC TROGLITAZONE IN NIDDK TYPE II PREVENTION TRIAL, NDA SLATED FOR SUMMER

Executive Summary

One-quarter of the use of Warner-Lambert's anti-epileptic Neurontin (gabapentin) is for "conditions other than epilepsy," Parke-Davis Chairman Ronald Cresswell, PhD, told securities analysts April 11 in New York City. "We are aggressively investigating the effects of Neurontin on psychological conditions such as bipolar disorders and social phobias," Cresswell said. "We have begun multi-center pain studies in neuropathic pain and in post-herpetic neuralgia," he added. Sales of Neurontin in 1995 totaled $102 mil.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel